CDK4 and breast cancer: Palbociclib, a CDK4/6 inhibitor, has demonstrated significant therapeutic benefit in HR+ breast cancer; however, acquired resistance to CDK4/6 inhibition has been widely reported in both clinical and preclinical studies16,17.